| 1 |
Hao L, Zhang J, Liu Z, Lin X, Guo J. Epitranscriptomics in the development, functions, and disorders of cancer stem cells. Front Oncol 2023;13. [DOI: 10.3389/fonc.2023.1145766] [Reference Citation Analysis]
|
| 2 |
Di Cristofano F, George A, Tajiknia V, Ghandali M, Wu L, Zhang Y, Srinivasan P, Strandberg J, Hahn M, Sanchez Sevilla Uruchurtu A, Seyhan AA, Carneiro BA, Zhou L, Huntington KE, El-Deiry WS. Therapeutic targeting of TRAIL death receptors. Biochem Soc Trans 2023;51:57-70. [PMID: 36629496 DOI: 10.1042/BST20220098] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 3 |
Xia J, Li S, Liu S, Zhang L. Aldehyde dehydrogenase in solid tumors and other diseases: Potential biomarkers and therapeutic targets. MedComm (2020) 2023;4:e195. [PMID: 36694633 DOI: 10.1002/mco2.195] [Reference Citation Analysis]
|
| 4 |
Di Cristofano FR, Fong MW, Huntington KE, Carneiro BA, Zhou L, El-Deiry WS. Synergistic activity of ABT-263 and ONC201/TIC10 against solid tumor cell lines is associated with suppression of anti-apoptotic Mcl-1, BAG3, pAkt, and upregulation of pro-apoptotic Noxa and Bax cleavage during apoptosis. Am J Cancer Res 2023;13:307-25. [PMID: 36777502] [Reference Citation Analysis]
|
| 5 |
Drakulic D, Schwirtlich M, Petrovic I, Mojsin M, Milivojevic M, Kovacevic-grujicic N, Stevanovic M. Current Opportunities for Targeting Dysregulated Neurodevelopmental Signaling Pathways in Glioblastoma. Cells 2022;11:2530. [DOI: 10.3390/cells11162530] [Reference Citation Analysis]
|
| 6 |
Wu L, Liang J, Li J, Xu Y, Chen J, Su Y, Xian Y, Wei J, Xu J, Zhao J, Liu Q, Yang Y. Onc201 reduces osteoclastogenesis and prevents ovariectomy-induced bone loss via inhibiting RANKL-induced NFATc1 activation and the integrin signaling pathway. Eur J Pharmacol 2022;923:174908. [PMID: 35405113 DOI: 10.1016/j.ejphar.2022.174908] [Reference Citation Analysis]
|
| 7 |
Püschel J, Dubrovska A, Gorodetska I. The Multifaceted Role of Aldehyde Dehydrogenases in Prostate Cancer Stem Cells. Cancers (Basel) 2021;13:4703. [PMID: 34572930 DOI: 10.3390/cancers13184703] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 8 |
He L, Bhat K, Ioannidis A, Zhang L, Nguyen NT, Allen JE, Nghiemphu PL, Cloughesy TF, Liau LM, Kornblum HI, Pajonk F. Effects of the DRD2/3 antagonist ONC201 and radiation in glioblastoma. Radiother Oncol 2021;161:140-7. [PMID: 34097975 DOI: 10.1016/j.radonc.2021.05.027] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 9 |
D'Alessandro G, Lauro C, Quaglio D, Ghirga F, Botta B, Trettel F, Limatola C. Neuro-Signals from Gut Microbiota: Perspectives for Brain Glioma. Cancers (Basel) 2021;13:2810. [PMID: 34199968 DOI: 10.3390/cancers13112810] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 10 |
Al Madhoun A, Haddad D, Al Tarrah M, Jacob S, Al-Ali W, Nizam R, Miranda L, Al-Rashed F, Sindhu S, Ahmad R, Bitar MS, Al-Mulla F. Microarray analysis reveals ONC201 mediated differential mechanisms of CHOP gene regulation in metastatic and nonmetastatic colorectal cancer cells. Sci Rep 2021;11:11893. [PMID: 34088951 DOI: 10.1038/s41598-021-91092-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 11 |
She X, Gao Y, Zhao Y, Yin Y, Dong Z. A high-throughput screen identifies inhibitors of lung cancer stem cells. Biomed Pharmacother 2021;140:111748. [PMID: 34044271 DOI: 10.1016/j.biopha.2021.111748] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 12 |
Saito M, Kishi R, Sasai T, Hatakenaka T, Matsuki N, Minagawa S. Effect of Nanog overexpression on the metastatic potential of a mouse melanoma cell line B16-BL6. Mol Cell Biochem 2021;476:2651-61. [PMID: 33665763 DOI: 10.1007/s11010-021-04110-8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 13 |
Chu M, Wan H, Zhang X. Requirement of splicing factor hnRNP A2B1 for tumorigenesis of melanoma stem cells. Stem Cell Res Ther 2021;12:90. [PMID: 33509274 DOI: 10.1186/s13287-020-02124-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 14 |
Zhang Y, Wang X. Targeting the Wnt/β-catenin signaling pathway in cancer. J Hematol Oncol 2020;13:165. [PMID: 33276800 DOI: 10.1186/s13045-020-00990-3] [Cited by in Crossref: 212] [Cited by in F6Publishing: 236] [Article Influence: 70.7] [Reference Citation Analysis]
|
| 15 |
Prabhu VV, Morrow S, Rahman Kawakibi A, Zhou L, Ralff M, Ray J, Jhaveri A, Ferrarini I, Lee Y, Parker C, Zhang Y, Borsuk R, Chang WI, Honeyman JN, Tavora F, Carneiro B, Raufi A, Huntington K, Carlsen L, Louie A, Safran H, Seyhan AA, Tarapore RS, Schalop L, Stogniew M, Allen JE, Oster W, El-Deiry WS. ONC201 and imipridones: Anti-cancer compounds with clinical efficacy. Neoplasia 2020;22:725-44. [PMID: 33142238 DOI: 10.1016/j.neo.2020.09.005] [Cited by in Crossref: 45] [Cited by in F6Publishing: 48] [Article Influence: 15.0] [Reference Citation Analysis]
|
| 16 |
He L, Bhat K, Ioannidis A, Zhang L, Nguyen NT, Allen JE, Nghiemphu PL, Cloughesy TF, Liau LM, Kornblum HI, Pajonk F. Synergistic Effects of the DRD2/3 Antagonist ONC201 and Radiation in Glioblastoma.. [DOI: 10.1101/2020.07.23.218446] [Reference Citation Analysis]
|
| 17 |
Garcia-Mayea Y, Mir C, Masson F, Paciucci R, LLeonart ME. Insights into new mechanisms and models of cancer stem cell multidrug resistance. Semin Cancer Biol 2020;60:166-80. [PMID: 31369817 DOI: 10.1016/j.semcancer.2019.07.022] [Cited by in Crossref: 90] [Cited by in F6Publishing: 82] [Article Influence: 30.0] [Reference Citation Analysis]
|
| 18 |
Stein MN, Malhotra J, Tarapore RS, Malhotra U, Silk AW, Chan N, Rodriguez L, Aisner J, Aiken RD, Mayer T, Haffty BG, Newman JH, Aspromonte SM, Bommareddy PK, Estupinian R, Chesson CB, Sadimin ET, Li S, Medina DJ, Saunders T, Frankel M, Kareddula A, Damare S, Wesolowsky E, Gabel C, El-Deiry WS, Prabhu VV, Allen JE, Stogniew M, Oster W, Bertino JR, Libutti SK, Mehnert JM, Zloza A. Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration. J Immunother Cancer 2019;7:136. [PMID: 31118108 DOI: 10.1186/s40425-019-0599-8] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 19 |
Hall MD, Odia Y, Allen JE, Tarapore R, Khatib Z, Niazi TN, Daghistani D, Schalop L, Chi AS, Oster W, Mehta MP. First clinical experience with DRD2/3 antagonist ONC201 in H3 K27M-mutant pediatric diffuse intrinsic pontine glioma: a case report. J Neurosurg Pediatr 2019;23:719-25. [PMID: 30952114 DOI: 10.3171/2019.2.PEDS18480] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 8.3] [Reference Citation Analysis]
|
| 20 |
Prabhu VV, Madhukar NS, Gilvary C, Kline CLB, Oster S, El-Deiry WS, Elemento O, Doherty F, VanEngelenburg A, Durrant J, Tarapore RS, Deacon S, Charter N, Jung J, Park DM, Gilbert MR, Rusert J, Wechsler-Reya R, Arrillaga-Romany I, Batchelor TT, Wen PY, Oster W, Allen JE. Dopamine Receptor D5 is a Modulator of Tumor Response to Dopamine Receptor D2 Antagonism. Clin Cancer Res 2019;25:2305-13. [PMID: 30559168 DOI: 10.1158/1078-0432.CCR-18-2572] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 6.6] [Reference Citation Analysis]
|
| 21 |
Zhou L, Sheng D, Wang D, Ma W, Deng Q, Deng L, Liu S. Identification of cancer-type specific expression patterns for active aldehyde dehydrogenase (ALDH) isoforms in ALDEFLUOR assay. Cell Biol Toxicol 2019;35:161-77. [PMID: 30220009 DOI: 10.1007/s10565-018-9444-y] [Cited by in Crossref: 49] [Cited by in F6Publishing: 40] [Article Influence: 9.8] [Reference Citation Analysis]
|
| 22 |
Ralff MD, El-Deiry WS. TRAIL pathway targeting therapeutics. Expert Rev Precis Med Drug Dev 2018;3:197-204. [PMID: 30740527 DOI: 10.1080/23808993.2018.1476062] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 23 |
Lev A, Lulla AR, Ross BC, Ralff MD, Makhov PB, Dicker DT, El-Deiry WS. ONC201 Targets AR and AR-V7 Signaling, Reduces PSA, and Synergizes with Everolimus in Prostate Cancer. Mol Cancer Res 2018;16:754-66. [PMID: 29588330 DOI: 10.1158/1541-7786.MCR-17-0614] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 24 |
Ralff MD, Lulla AR, Wagner J, El-Deiry WS. ONC201: a new treatment option being tested clinically for recurrent glioblastoma. Transl Cancer Res 2017;6:S1239-43. [PMID: 30175049 DOI: 10.21037/tcr.2017.10.03] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 25 |
Platts MM, Anastassiades E. Dialysis encephalopathy: precipitating factors and improvement in prognosis. Clin Nephrol. 1981;15:223-228. [PMID: 32456660 DOI: 10.1186/s13045-020-00901-6] [Cited by in Crossref: 58] [Cited by in F6Publishing: 63] [Article Influence: 1.4] [Reference Citation Analysis]
|
